Share Twitter LinkedIn Facebook Email Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute explains the outcomes from the phase II study of trilaciclib in small cell lung cancer (SCLC).
Lurbinectedin: Enhancing Immunotherapy Efficacy in Small Cell Lung Cancer Small Cell Lung Cancer 3 Mins Read
HARPOON THERAPEUTICS: New data on HPN328 T cell engager at ESMO 2023 Small Cell Lung Cancer 2 Mins Read
Emerging Treatment for SCLC – Leading Developments & Current Questions in Lung Cancer Small Cell Lung Cancer 1 Min Read